Cardiology pp 241-252 | Cite as

The Clinical Relevance of Partial Agonist Activity of Beta-Adrenoceptor Blocking Drugs

  • W. H. Aellig

Abstract

Beta-adrenoceptor blocking drugs are often considered first choice therapy in patients with mild hypertension who require medical therapy. This is due not only to their effectiveness but also to the low incidence of side-effects during long-term administration.

Keywords

Cardiac Output Clinical Pharmacology Peripheral Resistance Rest Heart Rate Haemodynamic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aellig, W. H., 1979, Nagra kliniskt farmakologiska experiment med β-adrenoceptorblockerande farmaka, in: 3. Basel Hypertoni Saposiet, pp.29–33, L. Hansson and O. Thulesius, eds.Google Scholar
  2. Aellig, W. H., 1982a, Pindolol — A β-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological consideration, Br.J.Clin.Pharmac, 13:187S–192S.CrossRefGoogle Scholar
  3. Aellig, W. H., 1982b, Clinical pharmacology of pindolol, Am.Heart J., 104:346.PubMedCrossRefGoogle Scholar
  4. Carruthers, S. G. and Twum-Barima, Y., 1981, Measurement of partial agonist activity of pindolol in man, Clin.Pharmac.Ther. 30: 581–586.CrossRefGoogle Scholar
  5. Clark, B. J., Menninger, K., and Bertholet, A., 1982, Pindolol the pharmacology of a partial agonist., Br. J. Clin. Pharmac., 13:149S–158S.CrossRefGoogle Scholar
  6. Erikssen, J., Thaulow, E., Mundal, R., Opstad, P., and Nitter-Hauge, S., 1982, Comparison of β-adrenoceptor blockers under maximal exercise (pindolol v metoprolol v atenolol), Br.J. Clin. Pharmac, 13:201S–209S.CrossRefGoogle Scholar
  7. Jennings, G., Bobik, A., and Korner, P., 1981, Influence of intrinsic sympathomimetic activity of β-adrenoceptor blockers on the heart rate and blood pressure responses to graded exercise, Br.J.Clin.Pharmac., 12:355–362.CrossRefGoogle Scholar
  8. Lehtonen, A., Hietanen, E., Marniemi, J., Peltonen, P., and Niskanen, J., 1982, Effect of pindolol on serum lipids and lipid metabolizing enzymes, Br.J.Clin.Pharmac., 13:445S–448S.CrossRefGoogle Scholar
  9. Leren, P., Eide, I., Foss, O. P., Helgeland, A., Hjermann, I., Holme, I., Kjeldsen, S. E., and Lund-Larsen, P.G., 1982, Antihypertensive drugs and blood lipids: the Oslo study, Br.J.Clin.Pharmac., 13:441S–444S.CrossRefGoogle Scholar
  10. Louis, W. J., and McNeil, J. J., 1982, β-adrenoceptor blocking drugs: the relevance of intrinsic sympathomimetic activity, Br.J.Clin.Pharmac, 13:317S–320S.CrossRefGoogle Scholar
  11. Man in’t Veld, A. J., and Schalekamp, M. A. D. H., 1982, How intrinsic sympathomimetic activity modulates the haemodynamic responses to β-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism, Br.J.Clin.Pharmac., 13: 245S–257S.CrossRefGoogle Scholar
  12. Pasotti, C., Capra, A., Fiorella, G., Vibelli, C. and Chierichetti, S. M., 1982, Effects of pindolol and metoprolol on plasma lipids and lipoproteins, Br.J.Clin.Pharmac., 13:435S–439S.CrossRefGoogle Scholar
  13. Prichard, B. N. C., 1974, β-adrenoceptor blocking drugs in angina pectoris, Drugs, 7:55–84.PubMedCrossRefGoogle Scholar
  14. Prichard, B. N. C., Bhattacharjee, P., Tomlinson, B., and Waiden, R. J., 1982, The withdrawal of β-adrenergic blocking drugs, (same volume).Google Scholar
  15. Rangno, R. E., and Langlois, S., 1982, Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol, Br.J. Clin.Pharmac, 13:345S–351S.CrossRefGoogle Scholar
  16. Rosenthal, J., Kaiser, H., Raschig, A., and Welzel, D., 1979, Treatment of hypertension with a β-adrenoceptor blocker. A multicenter trial with pindolol, Br.J.Clin.Pract., 33:165–174, 181.PubMedGoogle Scholar
  17. Schlüter, K. J., Aellig, W. H., Petersen, K.-G., Rieband, H.-Ch., Wehrli, A., and Kerp, L., 1982, The influence of β-adrenoceptor blocking drugs with and without intrinsic sympathomimetic activity on the hormonal responses to hypo- and hyperglycaemia, Br.J.Clin.Pharmac., 13:407–417S.CrossRefGoogle Scholar
  18. Simpson, F. O., and Waal-Manning, H. J., 1970, Hypertension and β-adrenergic blockade, New Horizons Med., 1:59–72.Google Scholar
  19. Svendsen, T. L., Hartling, O., and Trap-Jensen, J., 1979, Immediate haemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI 89.406 in healthy volunteers, Eur.J.Clin. Pharmacol., 15:223–228.PubMedCrossRefGoogle Scholar
  20. Svendsen, T. L., Hartling, O. J., Trap-Jensen, J., McNair, A., and Bliddal, J., 1981, Adrenergic β-receptor blockade: Hemodynamic importance of intrinsic sympathomimetic activity at rest, Clin.Pharmacol.Ther., 29, 6, 711–718.PubMedCrossRefGoogle Scholar
  21. Szécsi, E., Kohlschütter, S., Schiess, W., and Lang, E., 1982, Abrupt withdrawal of pindolol or metoprolol after chronic therapy, Br.J.Clin.Pharmac., 13:353S–357S.CrossRefGoogle Scholar
  22. Waal-Manning, H. J., 1979, Can β-blockers be used in diabetic patients? Drugs, 17:157–160.PubMedCrossRefGoogle Scholar
  23. Waiden, R. J., Bhattacharjee, P., Tomlinson, B., Cashin, J., Graham, B. R., and Prichard, B. N. C., 1982, The effect of intrinsic sympathomimetic activity on β-receptor responsiveness after β-adrenoceptor blockade withdrawal, Br.J.Clin. Pharmac, 13:359S–364S.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • W. H. Aellig
    • 1
  1. 1.Experimental Therapeutics DepartmentClinical Research Division, Sandoz Ltd.BaselSwitzerland

Personalised recommendations